Home Cart Sign in  
Chemical Structure| 855527-92-3 Chemical Structure| 855527-92-3

Structure of NBI-74330
CAS No.: 855527-92-3

Chemical Structure| 855527-92-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NBI-74330 is a small molecule antagonist for CXCR3, NBI-74330 demonstrates potent inhibition of [(125)I]CXCL10 and [(125)I]CXCL11 specific binding (K (i) of 1.5 and 3.2 nM, respectively.

Synonyms: NBI-74330

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NBI-74330

CAS No. :855527-92-3
Formula : C32H27F4N5O3
M.W : 605.58
SMILES Code : O=C(N([C@@H](C1=NC2=NC=CC=C2C(N1C3=CC=C(OCC)C=C3)=O)C)CC4=CC=CN=C4)CC5=CC=C(F)C(C(F)(F)F)=C5
Synonyms :
NBI-74330
MDL No. :MFCD11850718
InChI Key :XMRGQUDUVGRCBS-UHFFFAOYSA-N
Pubchem ID :10167713

Safety of NBI-74330

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of NBI-74330

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Astroglial cells 100 nM 24 hours To investigate the effect of NBI-74330 on the release of pronociceptive factors by astroglial cells. Results showed that NBI-74330 reduced the expression of CCL4 and CXCL9. Int J Mol Sci. 2021 Oct 14;22(20):11074
Microglial cells 100 nM 24 hours To investigate the effect of NBI-74330 on the release of pronociceptive factors (IL-1β, IL-18, CCL6-7, CXCL4, CXCL9-10) by microglial cells. Results showed that NBI-74330 significantly reduced the expression of these factors. Int J Mol Sci. 2021 Oct 14;22(20):11074
DO11.10 cells 30-300 nM 60 minutes To evaluate the antagonistic effect of NBI-74330 on CXCL11-induced CXCR3 internalization. Results showed that NBI-74330 at 30-300 nM significantly right-shifted the CXCL11 E/[A] curve. Br J Pharmacol. 2007 Dec;152(8):1260-71

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Chronic constriction injury of the sciatic nerve (CCI) Intrathecal injection 10 µg/5 µL 16 and 1 hour before CCI, then once daily for 7 days To investigate the effect of NBI-74330 on mechanical and thermal hypersensitivity in CCI model rats. Results showed that NBI-74330 significantly alleviated mechanical and thermal hypersensitivity and reduced the expression of pronociceptive factors in the spinal cord and dorsal root ganglia. Int J Mol Sci. 2021 Oct 14;22(20):11074
Balb/c mice Balb/c mice Oral or subcutaneous injection 100 mg/kg Single dose To evaluate the pharmacokinetic and pharmacodynamic properties of NBI-74330 in mice. Results showed that the N-oxide metabolite of NBI-74330 exhibited CXCR3 antagonistic activity in vivo, and significant antagonism was observed 24 hours after subcutaneous administration. Br J Pharmacol. 2007 Dec;152(8):1260-71
Mice GL261 murine model of malignant glioma Subcutaneously injected 100 mg/kg/day Daily for 12 days NBI-74330 prolonged median survival times of both tumor-bearing WT and CXCR3-deficient mice when compared with vehicle-treated groups. NBI-74330 treatment did not impact tumor infiltration of lymphocytes and microglia. Carcinogenesis. 2011 Feb;32(2):129-37
Mice Dry skin and allergic contact dermatitis models Intrathecal injection 20 μg Single injection NBI-74330 significantly reduced scratching behavior, indicating that spinal CXCR3 plays an important role in dry skin-induced chronic itch. Neurosci Bull. 2018 Feb;34(1):54-63
Medaka (Oryzias latipes) Osteoporosis model Fish medium 30 μM 3 hours prior to heat shock, continued throughout the experiment NBI-74330 reduces macrophage recruitment and osteoclast formation by inhibiting Cxcr3.2, protecting bone integrity Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19276-19286

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.65mL

0.33mL

0.17mL

8.26mL

1.65mL

0.83mL

16.51mL

3.30mL

1.65mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories